The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: A meta-analysis

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6791-6799

  Yang, Yanlong ^a   Xian, Lei ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

GSTM1; GSTP1; Meta analysis; NSCLC; Pharmacogenetics; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN;

ALLELE; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CAUCASIAN; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84904962235     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1866-4     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi:10.3322/caac.20073.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80. doi:10.1056/NEJMra0802714.
3. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006;130(4):1211-9. doi:10.1378/chest.130.4.1211. (Pubitemid 44583755)
4. Custodio AB, Gonzalez-Larriba JL, Bobokova J, Calles A, Alvarez R, Cuadrado E, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4(7):891 - 910. doi:10.1097/JTO.0b013e3181a4b8fb.
5. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9-23. doi:10.1016/j.ctrv.2006.09.006. (Pubitemid 46137553)
6. Mannervik B, Danielson UH. Glutathione transferases - structure and catalytic activity. CRC Crit Rev Biochem. 1988;23(3):283-337.
7. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;75(3):173-234. doi:10.1016/j.critrevonc.2009.11.006.
8. Ikeda K, Miura K, Himeno S, Imura N, Naganuma A. Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum. Mol Cell Biochem. 2001;219(1-2):51-6. (Pubitemid 32331444)
9. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev. 2009;35(1):18-31. doi:10.1016/j.ctrv.2008.07.003.
10. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30(6):445-600. doi:10.3109/10409239509083491.
11. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal SS, Srivastava SK, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994;224(3):893-9. (Pubitemid 24288851)
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14. (Pubitemid 11167383)
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. doi:10.1136/bmj.327.7414.557. (Pubitemid 37088507)
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. (Pubitemid 17189972)
17. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, et al. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer. 2012;118(9):2466-75. doi:10.1002/cncr.26562.
18. Zhang YP, Sheng GF, Liu YP, Xue HP, Ling Y. The relationship of GSTP1 and clinical response to platinum based chemotherapy in advanced non-small cell lung cancer. J Med Theory Practice. 2012;25(24):3003-4.
19. Li W, Yue W, Zhang L, Zhao X, Ma L, Yang X, et al. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung. 2012;190(1):91-8. doi:10.1007/s00408-011-9338-8.
20. Zhou F, Yu Z, Jiang T, Lv H, Yao R, Liang J. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly. 2011;141:w13275. doi:10.4414/smw.2011.13275.
21. Sun N, Sun X, Chen B, Cheng H, Feng J, Cheng L, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(3):437-46. doi:10.1007/s00280-009-1046-1.
22. Yue Z, Xu Q, Xu Y, Dong NN, Zhang Y, Zhu LB, et al. GSTP 1 gene polymorphism and susceptibility as well as chemotherapy sensitivity to non-small cell lung cancer. Chin J Cancer Prev Treat. 2009;16(19):1441-4.
23. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118-23. doi:10.3816/CLC.2009.n.015.
24. Mao Y, Huang CH, Hua D, Deng JZ, Wei W, Yao Q. The relationshhip between glutathione S-transferase gene polymorphisms and chemotherapy response in NSCLC patients. Shandong Med J. 2007;47(36):68-9.
25. Booton R, Ward T, Heighway J, Ashcroft L, Morris J, Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol. 2006;1(7):679-83. (Pubitemid 47163956)
26. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One. 2012;7(6):e38150. doi:10.1371/journal.pone.0038150.
27. Gong M, Dong W, Shi Z, Xu Y, Ni W, An R. Genetic polymorphisms of GSTM1, GSTT1, and GSTP1 with prostate cancer risk: a meta-analysis of 57 studies. PLoS One. 2012;7(11):e50587. doi:10.1371/journal.pone.0050587.